The growing prevalence of ultrahigh-cost drugs under development is prompting health systems nationwide to rethink strategies ...
Novo Nordisk will pay $200 million up front, with up to $1.8 billion in additional payments down the line, The Wall Street ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback